ABT-510
Also known as: ABT-510, ABT‑510, thrombospondin mimetic, Thrombospondin‑1 mimetic peptide, TSP-1 mimetic peptide
Source ABT-510 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
ABT-510 is an investigational synthetic nonapeptide that mimics the anti‑angiogenic protein thrombospondin‑1. It has been evaluated in early‑phase clinical studies for several solid tumours, including glioblastoma, metastatic melanoma, renal cell carcinoma and soft‑tissue sarcoma, as well as in veterinary trials of canine sarcoma. The peptide is intended to inhibit tumour blood‑vessel formation and thereby slow cancer growth.
Mechanism of Action
ABT‑510 reproduces key structural elements of thrombospondin‑1, a natural inhibitor of angiogenesis. By binding to receptors that thrombospondin‑1 engages (such as CD36 on endothelial cells), the peptide blocks pro‑angiogenic signalling pathways, reduces endothelial cell proliferation and migration, and lowers circulating VEGF‑A and VEGF‑C levels, collectively limiting new blood‑vessel formation that supports tumour growth.
What the Research Shows
A 2005 oncology review listed ABT‑510 among emerging non‑peptide agents for renal cell carcinoma, noting acceptable toxicity. A 2008 sarcoma overview highlighted it as a promising anti‑angiogenic partner. In a phase I glioblastoma trial (23 patients), subcutaneous doses up to 200 mg day⁻¹ were well tolerated with median progression at 45.9 weeks and overall survival of 64.4 weeks; no dose‑limiting toxicities were observed. A phase II melanoma study (21 patients) using 100 mg twice daily was stopped early because only 3 patients remained progression‑free at 18 weeks, although VEGF reductions were documented. A veterinary study in 62 dogs with soft‑tissue sarcoma showed modest tumour responses (23 % overall, higher with ABT‑898 formulations) and a low incidence of non‑dose‑limiting adverse events. Overall, evidence is limited to early‑phase and pre‑clinical investigations.
Reported Benefits
Early trials indicate that ABT‑510 can be administered safely, with mainly mild injection‑site reactions and no severe dose‑limiting toxicities reported in humans. Biomarker analyses in melanoma showed reductions in circulating VEGF‑A, VEGF‑C and endothelial cell markers, suggesting on‑target anti‑angiogenic activity. The glioblastoma study reported disease‑stabilisation times comparable to standard therapy, supporting its potential as a combination partner.
Limitations of the Evidence
Clinical efficacy as a single agent remains unproven; the melanoma phase II trial failed to meet its primary endpoint and was terminated early. Sample sizes are small, and no maximum tolerated dose was defined in glioblastoma. Activity appears more pronounced in animal models, and the peptide has not progressed to late‑phase trials or regulatory approval. Consequently, the therapeutic value of ABT‑510 is still uncertain.
Safety Considerations
Across studies, ABT‑510 was generally well tolerated. Human trials reported only mild adverse events, chiefly injection‑site reactions, with no grade 3/4 toxicities attributable to the drug. In dogs, two non‑dose‑limiting toxicities (keratitis and osteoarthritis) were observed. Standard safety monitoring includes assessment of injection sites and routine laboratory testing, especially when combined with chemotherapy or radiotherapy.
How It Is Administered
ABT‑510 is delivered as a peptide injection, studied both subcutaneously (dose ranges 20–200 mg day⁻¹ in glioblastoma, 100 mg twice daily in melanoma) and intravenously in some protocols. Formulations are supplied as sterile solutions for injection; dosing schedules have varied according to trial design and combination regimens.
Routes of Administration
Goals & Uses
- Solid tumor treatmentOncologyLow
- solid tumor cancer therapyOncologyModerate
- anti‑angiogenic cancer therapyOncologyModerate
- Tumor angiogenesis inhibitionOncology / AntiangiogenicModerate
- ocular neovascular diseaseOphthalmologyLow
- Combination antiangiogenic therapyOncology / CombinationLow
Contraindications
- known hypersensitivity to peptideImmunologicModerate
- Known hypersensitivity to ABT-510 or peptide excipientsAllergyHigh
- hypersensitivity to peptide componentsAllergyModerate
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
Adverse Effects
- HypertensionCardiovascularUncommonHigh blood pressure
- Injection site reactionsLocalCommon
- Injection site painLocalCommonPain at the injection site
- ThrombocytopeniaHematologicUncommonLow platelet count
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- FatigueGeneralCommonLow energy or tiredness
- Injection site erythemaLocalCommonRedness at the injection site
Drug Interactions
- Cytotoxic chemotherapy agentsModerate
- none identifiedLow
- Anticoagulants / antiplatelet agentsModerate
- other anti‑angiogenic agents (e.g., bevacizumab)Moderate
Population Constraints
- Severe hepatic or renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Pregnant or lactating womenReproductiveAbsolute
- Pregnant womenReproductiveAbsolute
Regulatory Status
- European UnionInvestigationalUnder clinical investigation; not authorized
- United StatesInvestigationalInvestigational New Drug (IND) status; no FDA approval
- United KingdomInvestigationalNo marketing authorization
Not approved by FDA or EMA; studied in Phase II trials for melanoma, renal cell carcinoma, and sarcoma.
Evidence & Sources
- Journal ArticleModerateAmato RJ2005-01-01T00:00:00.000000Z
- Journal ArticleModerateKopp HG, et al.2008-01-01T00:00:00.000000Z
- Journal ArticleModerateNabors LB, et al.2010-01-01T00:00:00.000000Z
- Journal ArticleModerateMarkovic SN, et al.2007-01-01T00:00:00.000000Z
- Journal ArticleModerateSahora AI, et al.2012-01-01T00:00:00.000000Z
- Journal ArticleModerateBayes M, Rabasseda X, Prous JR2006-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of cancer has ABT‑510 been tested in?
It has been investigated in early‑phase studies for glioblastoma, metastatic melanoma, renal cell carcinoma, and soft‑tissue sarcoma, as well as in a veterinary trial of canine soft‑tissue sarcoma.
Is ABT‑510 approved for clinical use?
No. ABT‑510 remains an investigational agent and has not received regulatory approval for any indication.
How is ABT‑510 administered?
The peptide is given by injection, most commonly subcutaneously, using sterile solution formulations; intravenous administration has also been explored in some studies.
What are the main safety concerns?
Clinical studies have reported mainly mild injection‑site reactions. No severe dose‑limiting toxicities were identified in humans, though occasional non‑dose‑limiting events such as keratitis and osteoarthritis occurred in canine trials.
Does ABT‑510 improve survival?
In a small glioblastoma phase I trial, median overall survival was about 64 weeks, but the study was not designed to assess efficacy definitively, and other trials (e.g., melanoma) did not demonstrate clear survival benefit.
What is ABT-510?
ABT-510 is an investigational synthetic nonapeptide that mimics the anti‑angiogenic protein thrombospondin‑1. It has been evaluated in early‑phase clinical studies for several solid tumours, including glioblastoma, metastatic melanoma, renal cell carcinoma and soft‑tissue sarcoma, as well as in veterinary trials of canine sarcoma. The peptide is intended to inhibit tumour blood‑vessel formation and thereby slow cancer growth.
What is ABT-510 used for?
ABT-510 is educationally associated with: Solid tumor treatment, solid tumor cancer therapy, anti‑angiogenic cancer therapy, Tumor angiogenesis inhibition, ocular neovascular disease, Combination antiangiogenic therapy. Educational only — not medical advice.
How is ABT-510 administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of ABT-510?
Reported adverse effects include: Hypertension, Injection site reactions, Injection site pain, Thrombocytopenia, Nausea, Fatigue, Injection site erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid ABT-510?
Recorded contraindications: known hypersensitivity to peptide, Known hypersensitivity to ABT-510 or peptide excipients, hypersensitivity to peptide components, Pregnancy. Consult a qualified clinician before use.